Core Viewpoint - Haier Biomedical's stock closed at 30.92 yuan, down 1.34%, with a rolling PE ratio of 28.98 times, and a total market value of 9.831 billion yuan [1] Company Overview - Qingdao Haier Biomedical Co., Ltd. focuses on providing optimal user experiences for life science users, including pharmaceutical companies, research institutions, and healthcare users, forming two main business segments: life sciences and medical innovation [2] - The company offers comprehensive digital solutions represented by smart laboratories, digital hospitals, and smart public health, with key products including low-temperature storage boxes, automated biological sample storage, and various automated medication products [2] Financial Performance - In Q1 2025, the company reported revenue of 689 million yuan, a year-on-year increase of 0.30%, and a net profit of 110 million yuan, a year-on-year decrease of 19.88%, with a gross profit margin of 48.35% [3] - The company's PE ratio is significantly lower than the industry average of 48.92 times and the industry median of 35.68 times, ranking 66th in the industry [3]

Group 1 - The trend of Chinese medical device companies "going global" is long-term positive, especially in the upstream supply chain which has formed a certain scale [1] - In Q1 2025, China's medical device export trade total is projected to reach 69.26 billion yuan, a year-on-year increase of 5.03%, with high-end medical devices seeing significant growth [1] - The export value of China's medical device industry is expected to reach 48.75 billion USD in 2024, reflecting a year-on-year growth of 7.3% [1] Group 2 - Over 100 listed medical device companies have already initiated "going global" operations in 2024, covering various product areas such as medical consumables and diagnostic equipment [2] - Companies are advised to consider business, supply chain, and localization strategies for global expansion [2][3] - Localized production and supply chain management are essential for adapting to market demands in different regions [3] Group 3 - Companies like Haier Bio emphasize the importance of localizing product design and marketing to enhance user experience in overseas markets [4] - The trend of "going global" is common among mature, growth, and startup medical device companies, focusing on high-value and high-end products [6] - High-value medical devices, such as deep brain stimulators, require careful economic calculations and long-term service planning before entering foreign markets [6] Group 4 - Companies are encouraged to leverage digitalization and smart technologies to enhance their global strategies, as seen with Mindray Medical's remote monitoring capabilities [7] - Brand building is crucial for domestic medical device companies, with strategies including sponsorship of international sports events to enhance global influence [7] - The medical device market in Europe and the US accounts for over 65% of the global market share, making it a primary target for Chinese companies [8] Group 5 - Key conditions for Chinese medical device companies to "go global" include having sufficient capital, production capacity, and independent R&D capabilities [8] - Collaboration with local hospitals and doctors for joint R&D and clinical trials can facilitate product entry into new markets [8]

Core Viewpoint - Haier Biomedical's stock closed at 31.9 yuan, down 1.09%, with a rolling PE ratio of 29.90 times, and a total market value of 10.143 billion yuan [1] Group 1: Company Overview - Haier Biomedical focuses on providing optimal user experiences for life science users, including pharmaceutical companies, research institutions, and healthcare users [2] - The company has developed two main business segments: life sciences and medical innovation, offering comprehensive digital solutions such as smart laboratories and digital hospitals [2] - Key products include low-temperature storage boxes, automated biological sample storage systems, and various automated medication products [2] Group 2: Financial Performance - In the first quarter of 2025, the company reported revenue of 689 million yuan, a year-on-year increase of 0.30%, and a net profit of 110 million yuan, a year-on-year decrease of 19.88% [3] - The gross profit margin for sales was 48.35% [3] Group 3: Market Position - The average PE ratio for the medical device industry is 48.98 times, with a median of 36.16 times, placing Haier Biomedical at the 70th position in the industry [1][3] - As of the first quarter of 2025, 14 institutions held shares in Haier Biomedical, with a total holding of 200.17 million shares valued at 6.922 billion yuan [1]

Company Overview - Qingdao Haier Biomedical Co., Ltd. focuses on providing optimal user experiences for life science users, including pharmaceutical and biological enterprises, research institutions, hospitals, and public health organizations [2] - The company has developed two main business segments: life sciences and medical innovation, offering comprehensive digital solutions such as smart laboratories and digital hospitals [2] Financial Performance - For Q1 2025, the company reported revenue of 689 million yuan, a year-on-year increase of 0.30%, and a net profit of 110 million yuan, representing a year-on-year decrease of 19.88% [3] - The gross profit margin for the period was 48.35% [3] Market Position - As of May 6, the company's stock closed at 31.95 yuan, with a rolling price-to-earnings (PE) ratio of 29.94 times, and a total market capitalization of 10.159 billion yuan [1] - The average PE ratio in the medical device industry is 48.90 times, with a median of 36.41 times, placing the company at the 69th position in the industry ranking [1] Shareholder Information - As of March 31, 2025, the number of shareholders for the company was 12,793, a decrease of 453 from the previous count, with an average holding value of 352,800 yuan per shareholder and an average holding of 27,600 shares [1] Product and Innovation - The company's main products include low-temperature storage boxes, automated biological sample storage systems, and various automated medication products, among others [2] - In 2022, the company received several prestigious awards and certifications, enhancing its reputation in the life sciences and medical innovation sectors [2]

证券代码：688139 证券简称：海尔生物 公告编号：2025-036 青岛海尔生物医疗股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 法律责任。 本次回购股份符合法律法规的规定及公司回购股份方案。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出 回购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务， 敬请广大投资者注意投资风险。 重要内容提示： 青岛海尔生物医疗股份有限公司（以下简称"公司"）于 2025 年 1 月 13 日召 开第三届董事会第四次会议，审议通过了《关于以集中竞价交易方式回购公司股 份方案的议案》（以下简称"本次回购方案"），同意公司以自有资金通过上海证券 交易所股票交易系统以集中竞价交易方式回购公司已发行的部分人民币普通股（A 股）。回购的股份将在未来适宜时机全部用于员工持股计划或股权激励，回购价格 不超过 50 元/股（含），回 ...

Investment Rating - The report maintains a "Recommendation" rating for Haier Biomedical (688139) [1] Core Views - The company reported Q1 2025 revenue of 689 million yuan, a slight increase of 0.30% year-on-year, while net profit attributable to shareholders decreased by 19.88% to 110 million yuan [1] - Non-storage new industries continue to maintain high growth, with overseas business returning to stable growth [1] - The company expects net profit attributable to shareholders for 2025-2027 to be 440 million, 540 million, and 640 million yuan, with year-on-year growth rates of 20.6%, 23.1%, and 18.3% respectively [7] Financial Performance Summary - Total revenue forecast for 2024A is 2,284 million yuan, with expected growth rates of 0.1% in 2024, 15.2% in 2025, 16.4% in 2026, and 13.2% in 2027 [3] - The net profit attributable to shareholders is projected to decline by 9.7% in 2024, followed by increases of 20.6%, 23.1%, and 18.3% in the subsequent years [3] - The earnings per share (EPS) is expected to rise from 1.15 yuan in 2024 to 2.02 yuan in 2027 [3] Business Segment Performance - The low-temperature storage business showed a narrowing decline, with a return to positive growth in Q4 2024 and continued improvement in Q1 2025 [7] - Non-storage new industries accounted for 44% of revenue in Q1 2025, with a year-on-year growth of 13.92% and a quarter-on-quarter growth of 27.35% [7] - Domestic revenue in Q1 2025 was 482 million yuan, a decrease of 3.35% year-on-year but an increase of 54.98% quarter-on-quarter [7] Investment Recommendations - The report maintains the profit forecast unchanged, with a target price of approximately 42 yuan based on a DCF model, corresponding to a total valuation of 13.3 billion yuan [7] - The company is expected to achieve a price-to-earnings (PE) ratio of 23, 19, and 16 for the years 2025, 2026, and 2027 respectively [3]

Core Viewpoint - Haier Biomedical's Q1 revenue reached 688.99 million, a year-on-year increase of 0.30%, indicating a return to normal business development despite challenges in the market [2][3]. Revenue Summary - Total revenue for Q1 2025 was 688.99 million, compared to 686.91 million in the same period last year, reflecting a growth of 0.30% [3]. - Net profit attributable to shareholders decreased by 19.88% to 110.26 million, while the net profit after deducting non-recurring gains and losses fell by 25.38% to 99.17 million [3]. - Operating cash flow decreased significantly by 51.79% to 37.22 million [3]. - Basic and diluted earnings per share both dropped by 20.45% to 0.35 yuan [3]. Business Segment Performance - The Life Sciences segment generated revenue of 354 million, up 1.06% year-on-year and 53.28% quarter-on-quarter [3]. - The Medical Innovation segment reported revenue of 332 million, down 0.61% year-on-year but up 24.26% quarter-on-quarter [3]. Growth Drivers 1. Non-storage new industries maintained high growth, with revenue share at 44%, increasing by 13.92% year-on-year and 27.35% quarter-on-quarter, driven by growth in plasma consumables, medication automation, laboratory consumables, and instruments [4]. 2. Domestic scenario solutions continued to expand, with domestic market revenue at 482 million, down 3.35% year-on-year but up 54.98% quarter-on-quarter, enhancing brand strength and competitiveness [4]. 3. The overseas market showed signs of recovery with revenue of 204 million, a year-on-year increase of 9.88% and a quarter-on-quarter increase of 8.99%, reversing the decline seen in 2024 [4]. Future Industry Layout - Haier Biomedical is actively expanding into future industries such as CGT and blood management, launching an intelligent fully automated cell culture workstation and enhancing blood supply efficiency through AI and smart blood management systems [5].

Financial Overview - The company achieved total revenue of 689 million yuan in Q1 2025, a year-on-year increase of 0.3% [1] - The net profit attributable to the parent company was 110 million yuan, a year-on-year decrease of 19.88% [1] - The net profit excluding non-recurring items was 99.17 million yuan, a year-on-year decrease of 25.38%, indicating a decline in profitability despite slight revenue growth [1] Profit and Cost Analysis - The gross profit margin was 48.35%, an increase of 1.76 percentage points year-on-year, reflecting effective cost control [2] - The net profit margin was 16.86%, a year-on-year decrease of 18.33 percentage points, suggesting that other factors negatively impacted final profits despite improved gross margins [2] Expense Control - Total selling, administrative, and financial expenses reached 132 million yuan, accounting for 19.16% of revenue, which is a 38.24% increase compared to the same period last year, indicating pressure on expense control [3] Cash Flow and Assets Liabilities - The operating cash flow per share was 0.12 yuan, a year-on-year decrease of 51.79%, reflecting a deterioration in cash flow from operating activities [4] - Monetary funds decreased from 1.32 billion yuan to 831 million yuan, a decline of 37.02%, further highlighting cash flow pressures [4] Accounts Receivable and Debt Repayment Ability - As of the end of the reporting period, accounts receivable amounted to 432 million yuan, a year-on-year increase of 29.04%, with accounts receivable accounting for 117.8% of the latest annual net profit, which may adversely affect future cash flow [5] - Despite this, the company's cash assets remain in a healthy state [5] Business Model and Future Development - The company's performance relies heavily on research and marketing efforts, with cumulative financing of 1.231 billion yuan and cumulative dividends of 643 million yuan over the past six years, resulting in a dividend-to-financing ratio of 0.52 [6] - Moving forward, the company needs to focus more on the recovery of accounts receivable and improvement of cash flow to ensure sustainable development [6]

证券代码：688139 证券简称：海尔生物 公告编号：2025-034 青岛海尔生物医疗股份有限公司 关于注销部分募集资金专户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、募集资金基本情况 经上海证券交易所科创板股票上市委员会 2019 年 7 月 30 日审核同意，并经 中国证券监督管理委员会 2019 年 9 月 20 日下发《关于同意青岛海尔生物医疗股 份有限公司首次公开发行股票注册的批复》（证监许可[2019]1742 号）核准， 同意青岛海尔生物医疗股份有限公司（以下简称"公司"、"本公司"或"海尔 生物"）公开发行人民币普通股不超过 79,267,940 股，每股发行价格为人民币 15.53 元，募集资金总额为人民币 1,231,031,108.20 元，实际到账金额人民币 1,161,576,074.14 元，包括尚未划转的其他发行费用。上述募集资金于 2019 年 10 月 22 日到位，并经安永华明会计师事务所（特殊普通合伙）审验并出具了安 永华明（2019）验字第 61433766_J0 ...